Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherBrief Communication

Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer

Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo and Irene J. Virgolini
Journal of Nuclear Medicine January 2023, jnumed.122.264977; DOI: https://doi.org/10.2967/jnumed.122.264977
Elisabeth von Guggenberg
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Uprimny
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maximilian Klingler
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boris Warwitz
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Sviridenko
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steffen Bayerschmidt
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianpaolo Di Santo
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene J. Virgolini
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

PET/CT imaging was performed in patients with advanced medullary thyroid cancer (MTC) with the new 68Ga-labeled minigastrin analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (68Ga-DOTA-MGS5) to evaluate the cholecystokinin-2 receptor expression status. Methods: Six patients with advanced MTC underwent PET/CT imaging with 68Ga-DOTA-MGS5. From the images acquired one and two hours post injection (p.i.) preliminary data on the biodistribution and tumor targeting properties were evaluated in a retrospective analysis. Results: A total of 87 lesions with increased radiotracer uptake considered malignant (two local recurrence, eight lymph nodes, 27 liver and 50 bone lesions) was detected. In general, radiotracer accumulation in lesions was found higher two hours as compared to one hour p.i. (mean SUVmax/SUVmean of 7.2/4.4 versus 6.0/3.6). Conclusion: The preliminary results clearly demonstrate the potential of 68Ga-DOTA-MGS5 PET/CT in detecting local recurrence and metastases in patients with advanced MTC.

  • Oncology: Endocrine
  • Peptides
  • PET/CT
  • cholecystokin-2 receptor
  • gallium-68
  • medullary thyroid cancer
  • minigastrin
  • positron emission tomography
  • Copyright © 2023 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (3)
Journal of Nuclear Medicine
Vol. 64, Issue 3
March 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo, Irene J. Virgolini
Journal of Nuclear Medicine Jan 2023, jnumed.122.264977; DOI: 10.2967/jnumed.122.264977

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo, Irene J. Virgolini
Journal of Nuclear Medicine Jan 2023, jnumed.122.264977; DOI: 10.2967/jnumed.122.264977
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Brief Communication

  • Novel 68Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls
  • Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy
Show more Brief Communication

Clinical (Oncology: Endocrine/Neuroendocrine)

  • Novel 68Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls
  • Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy
  • The emergence of somatostatin antagonist-based theranostics: Paving the road toward another success?
Show more Clinical (Oncology: Endocrine/Neuroendocrine)

Similar Articles

Keywords

  • Oncology: Endocrine
  • Peptides
  • PET/CT
  • cholecystokin-2 receptor
  • gallium-68
  • medullary thyroid cancer
  • Minigastrin
  • Positron Emission Tomography
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire